R Maute,J Xu,I L Weissman
R Maute
CD47 is a "don't eat me" signal to phagocytes that is overexpressed on many tumor cells as a potential mechanism for immune surveillance evasion. CD47 and its interaction with signal-regulating protein alpha (SIRPα) on phagocytes is theref...
M Rashidian,H Ploegh
M Rashidian
Antibodies and antibody fragments have found wide application for therapeutic and diagnostic purposes. Single-domain antibody fragments, also known as 'heavy-chain variable domains' or 'nanobodies', are a recent addition to the toolbox. Dis...
Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation [0.03%]
同种异体造血细胞移植后肿瘤反应性B细胞和抗体应答情况
G de Jong,M A Gillissen,H Spits et al.
G de Jong et al.
For many high-risk haematologic malignancies, such as acute myeloid leukaemia, the success of therapy relies mainly on invoking a curative antitumour immune response. This can be achieved by inducing a graft-versus-leukaemia response follow...
Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform [0.03%]
肿瘤免疫治疗诱导的免疫反应的功能和空间综合分析：iPROFILER平台
V H Koelzer,P Herzig,I Zlobec et al.
V H Koelzer et al.
Background: Cancer immunotherapy elicits functional activation and changes in immune cell distribution in cancer. Tumour heterogeneity is a reason for treatment failure but is difficult to capture in experimental settings...
T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation [0.03%]
TCR交叉识别作用及筛选安全的临床用TCR策略
Amalie Kai Bentzen,Sine Reker Hadrup
Amalie Kai Bentzen
Adoptive transfer of T-cell-receptor (TCR)-transduced T cells has shown promising results for cancer treatment, but has also produced severe immunotoxicities caused by on-target as well as off-target TCR recognition. Off-target toxicities a...
John Haanen
John Haanen
J B Haanen
J B Haanen
J Haanen
J Haanen
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma [0.03%]
肿瘤浸润淋巴细胞与溶瘤腺病毒(TILT-123)联合治疗后，一例黏膜黑色素瘤患者的长期完全缓解响应
Background: Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, and ...